Nothing Special   »   [go: up one dir, main page]

Rich et al., 2011 - Google Patents

Survey of the 2009 commercial optical biosensor literature

Rich et al., 2011

Document ID
16560207888354595773
Author
Rich R
Myszka D
Publication year
Publication venue
Journal of Molecular Recognition

External Links

Snippet

We took a different approach to reviewing the commercial biosensor literature this year by inviting 22 biosensor users to serve as a review committee. They set the criteria for what to expect in a publication and ultimately decided to use a pass/fail system for selecting which …
Continue reading at onlinelibrary.wiley.com (other versions)

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • G01N33/569Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1037Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies

Similar Documents

Publication Publication Date Title
Rich et al. Survey of the 2009 commercial optical biosensor literature
Rich et al. Survey of the year 2006 commercial optical biosensor literature
US20240294662A1 (en) Human mesothelin chimeric antigen receptors and uses thereof
Rich et al. Survey of the year 2005 commercial optical biosensor literature
Lee et al. Decay of Fc-dependent antibody functions after mild to moderate COVID-19
Rich et al. Survey of the year 2007 commercial optical biosensor literature
Shiakolas et al. Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions
Burnie et al. The incorporation of host proteins into the external HIV-1 envelope
US9803193B2 (en) Protein screening methods
Meertens et al. The TIM and TAM families of phosphatidylserine receptors mediate dengue virus entry
Saini et al. The CXC chemokine receptor 4 ligands ubiquitin and stromal cell-derived factor-1α function through distinct receptor interactions
Claireaux et al. A public antibody class recognizes an S2 epitope exposed on open conformations of SARS-CoV-2 spike
WO2011100841A1 (en) Pd-1 modulation and uses thereof for modulating hiv replication
US10822406B2 (en) Method for treating chronic intestinal inflammation and inflammatory bowel disease by administering antagonists of Oncostatin-M (OSM) and/or antagonists of OSM receptor-beta (OSMR)
JP7186266B2 (en) Single domain antibodies directed against intracellular antigens
US20240369565A1 (en) Circulating Tumor Cell Enrichment Using Neoepitopes
Saitakis et al. Treatment and relapse prevention of typical and atypical optic neuritis
WO2015157561A1 (en) Specific and unique t cell responses and molecular signatures for treatment and diagnosis of mycobacterium tuberculosis
Barasa et al. Development of LB244, an irreversible STING antagonist
Labriola et al. Peptide–antibody fusions engineered by phage display exhibit an ultrapotent and broad neutralization of SARS-CoV-2 variants
WO2021097074A1 (en) Intestinal organoid co-culture systems and methods for treating or preventing a disease or disorder associated with immune response-mediated tissue injury
Haußner et al. Peptide Paratope Mimics of the Broadly Neutralizing HIV‐1 Antibody b12
JP6908710B2 (en) Chimeric antigen receptor (CAR) targeting the chemokine receptor CCR4 and its use
Warszawski et al. Design of a basigin‐mimicking inhibitor targeting the malaria invasion protein RH5
Shiakolas et al. Cross-reactive coronavirus antibodies with diverse epitope specificities and extra-neutralization functions